Navigation Links
ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
Date:4/17/2009

r demand for comprehensive R&D outsourcing."

Dmitry Prudnikov, CEO of PRUDENTAS LLC, noted: "Since its creation Prudentas focused on early phases of clinical trials, and integration with ChemDiv will allow our clients to get unique opportunity in studying their compounds with us from pre-clinical testing to Proof-of-Concept trials. Our such "solid program" integrated approach to increasing external R&D programs value will certainly save time and money for our clients, and creates an attractive proposition for many of our existing and potential sponsors.

About ChemDiv

ChemDiv, Inc. (ChemDiv) is a global contract research discovery and development organization headquartered in San Diego, CA, USA with subsidiaries in Russia, business and logistics operations around the world. ChemDiv provides external integrated discovery and development solutions to pharma and biotech partners based on the Discovery outSource(TM) platform. It covers the complete range of disciplines needed to bring a CNS, oncology, inflammation, metabolic and infectious disease projects from identification of a biological target to clinical drug and drug development candidates. Visit www.chemdiv.com for more information.

About Prudentas

PRUDENTAS is a Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team. PRUDENTAS appeared in response to the growing interest of pharmaceutical and biotech companies in conducting clinical trials in Russia and Ukraine, which resulted in the increasing number of clinical trials brought here within the last years.

PRUDENTAS aspires to mirror the highest international standards of service and
'/>"/>

SOURCE ChemDiv, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ChemDiv and Avineuro Extend Collaboration on Alzheimers Disease and Schizophrenia
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. ChemDiv and Achaogen Enter Into a Discovery Collaboration
4. Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
5. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
6. GSI Group Inc. to Restate Financial Results for 2006
7. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
8. Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That Positive Cash Flow Is Possible in 09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview
9. Bio-Matrix Scientific Group, Inc. Gets Updated Stock Recommendation By KonLin Investment Letter
10. Disabled and other vulnerable groups more susceptible to terrorism fears
11. Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures and Supporting the Economy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...SEATTLE, Nov. 19 Omeros ...ited financial results for the third quarter ended...ptember 30, 2009, Omeros reported a net loss of $3...et loss of $7.4 million, or $2.54 per share, for t...September 30, 2009, the Company reported a net los...
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-Fir...an innovator in biotechnology for diabetes therapy...lting services to food, supplement, biotechnology ...losed the previously reported $6.3 million registe... 2,760,870 shares of its common stock and warrants...
(Date:11/19/2009)...BETHESDA, Md., Nov. 19 S... in biotechnology for diabetes therapy, and a prov...es to food, supplement, biotechnology and pharmace...uesday,s Annual Meeting of Shareholders. ,, At ...(Nasdaq: SPEX ) elected the following members to ...
(Date:11/19/2009)..., MUNSTER, Germany, November 19 /PRNewswire/ ...filed on November 16th, 2009 Flibanserin in the,in...nesia in Parkinson,s,disease for orphan drug statu...EMEA). Levodopa-induced dyskinesia is a complicati...,s and a serious burden to some of those,affected,...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... Time -, SAN FRANCISCO, Nov. 10 Medivation, Inc....progress and financial,results for the quarter end...ented another quarter of significant,achievement a... partnering,agreement with Pfizer for Dimebon. Thi...d-class partner capable of maximizing global,comme...
... Discuss the Data and Ongoing ...Nov. 10 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ...1 clinical trial, one of Sangamo,s three Phase 2 c...am to develop SB-509 for diabetic,neuropathy (DN)....f the,drug is well tolerated in subjects with mild...
...es of Non-Core Product Lines -, HOPKINTON, Mass.,...LP ) today reported third quarter financial,result...divestitures: the,sale of its AutoTrace(R) product...he sale of its Pharmaceutical Development and Qual...on for $15.8 million. Revenues for the,quarter wer...
Other Biology Technology:Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11
(Date:11/23/2009)... Current research suggests that a common oral bact...ted report by Nichols et al, "Unique Lipids from a...LR2 Ligands Capable of Enhancing Autoimmunity," ap...Journal of Pathology . , Multiple sclerosis (MS)...ain and spinal cord, affects nearly 1 in 700 peopl...
(Date:11/23/2009)...The only swine vaccine available for the H1N1 viru... with the virus. The vaccination marks the first t...d with the pandemic flu., Iowa State University,...ped the vaccine this summer and has been shipping ...s and Illinois for several weeks., The latest va...
(Date:11/23/2009)...vember 16, 2009 -- A USDOE and USDA study conclude...pland, and cropland pasture could be converted fro...ses, such as switchgrass, from which biomass could...omically viable production of a perennial grass mo...mass are removed annually is expected to require n...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 1UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 2Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 1Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 2Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 51392 1Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 51392 2
...h, and still the University of Wisconsin-Madison S...requests. Since 1998, the school,s oncology depar...r dogs diagnosed with melanoma. Though it is sti...over the nation have wanted to participate in the ...heir pet. , After promising results from work done...
...we carry this activity out through the placenta an...velopment, the lungs of the foetus are filled with... activates this respiration surface. But the main ...ungs are not well formed. Moreover, they often lac...pids that avoids the lungs folding in on themselve...
...billion-base human genome play a vital role in a b...chers from the Wellcome Trust Sanger Institute and...r Medical Research, together with international co...ps of differences implicated in disease as well as... , The Major Histocompatibility Complex (MHC) con...
Other Biology News:Canine cancer vaccine program shows early promise 2Liquid ventilation 2Researchers map of genetic variations implicated in disease 2Researchers map of genetic variations implicated in disease 3
... CyScribe GFX Purification Kit, 25 reactions. For ...beled cDNA.Optimized reagents are packaged togethe...ible and optimized protocols can be used for perfo...abeled nucleotides.Reliable purification using the...
... Purification Kit, 24 reactions. For the generatio...timized reagents are packaged together for complet...mized protocols can be used for performing labelin...tides.Reliable purification using the CyScribe GFX...
Canine serum from Equitech-Bio
UV-NIR light source for USB2000, HR4000, HR2000+ from Ocean Optics
Biology Products: